Join us

Company Introduction

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. It is our company’s spirit that drives us forward.

We have established a globally integrated R&D process. With four R&D centers worldwide, we have the outstanding ability to discover and develop innovative biologics. We are able to independently perform crucial procedures, i.e. target assessments, mechanism studies and validation, clinical drug screening and functional validation, etc.

目前，公司具有50+项在研产品，覆盖五大治疗领域，包括恶性肿瘤、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病以及感染类疾病。凭借蛋白质工程核心平台技术，君实生物身处国际大分子药物研发前沿，获得了首个国产抗PD-1单克隆抗体NMPA上市批准、国产抗PCSK9单克隆抗体NMPA临床申请批准、全球首个治疗肿瘤抗BTLA阻断抗体在中国NMPA和美国FDA的临床申请批准，只为“打造世界一流、值得信赖的生物源创药普惠患者”。

We have two monoclonal antibody production bases in China with a combined fermentation capacity of 34,500L. The Suzhou Wujiang Production Base is responsible for pilot clinical drugs and commercial production. The Shanghai Lingang Production Base was built in accordance with CGMP standards and has been operating since the end of 2019.